These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38832710)

  • 41. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
    Bender Ignacio RA; Chew KW; Moser C; Currier JS; Eron JJ; Javan AC; Giganti MJ; Aga E; Gibbs M; Tchouakam Kouekam H; Johnsson E; Esser MT; Hoover K; Neytman G; Newell M; Daar ES; Fischer W; Fletcher CV; Li JZ; Greninger AL; Coombs RW; Hughes MD; Smith D; Wohl DA;
    JAMA Netw Open; 2023 Apr; 6(4):e2310039. PubMed ID: 37099295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era.
    Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N
    Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
    Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
    Transpl Int; 2024; 37():12061. PubMed ID: 38328617
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
    Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
    Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience.
    Akinosoglou K; Rigopoulos EA; Kaiafa G; Daios S; Karlafti E; Ztriva E; Polychronopoulos G; Gogos C; Savopoulos C
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
    Levin MJ; Ustianowski A; De Wit S; Beavon R; Thissen J; Seegobin S; Dey K; Near KA; Streicher K; Kiazand A; Esser MT
    Infect Dis Ther; 2024 Jun; 13(6):1253-1268. PubMed ID: 38703336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
    Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
    Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response.
    Braitsch K; Jeske SD; Stroh J; Hefter M; Platen L; Bachmann Q; Renders L; Protzer U; Götze KS; Herhaus P; Verbeek M; Spinner CD; Bassermann F; Högner M; Haller B; Schneider J; Heider M
    Vaccines (Basel); 2024 Aug; 12(8):. PubMed ID: 39203997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.
    Dluzynski D; Al-Shaikhly T; Paules CI; Henao MP
    J Allergy Clin Immunol Glob; 2024 Aug; 3(3):100293. PubMed ID: 39071730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
    Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
    Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Clegg LE; Stepanov O; Schmidt H; Tang W; Zhang H; Webber C; Cohen TS; Esser MT; Någård M
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158723. PubMed ID: 38534112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
    Levin MJ; Ustianowski A; Thomas S; Templeton A; Yuan Y; Seegobin S; Houlihan CF; Menendez-Perez I; Pollett S; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Ivanov S; Near KA; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
    Clin Infect Dis; 2023 Apr; 76(7):1247-1256. PubMed ID: 36411267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
    Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
    Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
    Esposito GL; Fassio F; Girardi D; Picasso E; Meloni F; Montini S; Codullo V; Pattonieri EF; Defrancesco I; Bianchessi A; Calvi M; Seminari EM; Baldanti F; Lilleri D; Novelli V; Marena C
    Vaccine; 2024 Oct; 42(23):126208. PubMed ID: 39154513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
    Woopen C; Konofalska U; Akgün K; Ziemssen T
    Front Immunol; 2022; 13():897748. PubMed ID: 35958567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
    Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
    Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
    [No Abstract]   [Full Text] [Related]  

  • 57. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
    Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
    Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19].
    Zhuravleva MV; Chulanov VP; Gagarina JV; Shabalina EA
    Ter Arkh; 2023 Feb; 95(1):66-77. PubMed ID: 37167117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC.
    Jondreville L; D'Aveni M; Labussière-Wallet H; Le Bourgeois A; Villate A; Berceanu A; Bezsera SM; Thiebaut A; Boissard-Simonet M; Legrand M; Cornillon J; Rubio MT; Chevallier P; Nguyen S
    J Hematol Oncol; 2022 Nov; 15(1):169. PubMed ID: 36443846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
    Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
    Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.